About
S-Biomedic develops viable skin-native probiotics derived from Cutibacterium to modulate the skin microbiome and provide microbiome-based active ingredients that address conditions such as acne, eczema, rosacea, and skin aging. The company collaborates with consumer skincare companies and is now a part of Beiersdorf.
Explore S-Biomedic's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.